Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
5,240.00
+230.00
+(4.59%)
At close: 3:30:30 PM GMT+9
Key Executives
Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in KRW.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Jaeseung Yoon | President & Co-CEO | -- | -- | 1961 |
| Inchul Chung | President & Co-CEO | -- | -- | -- |
PanGen Biotech Inc.
Innoplex 2-dong
4th Floor 306, Sinwon-ro Yeongtong-gu
Suwon-si, 16675
South Korea
- Sector:
- Healthcare
- Industry: Biotechnology
Description
PanGen Biotech Inc. operates as a biologics company in South Korea. It develops biosimilar products, such as EPO, recombinant factor VIII, G-CSF, etc. The company also provides CHO cell lines for proteins and monoclonal antibodies; and one-stop services ranging from producer cell line development to GMP production. In addition, it offers reagents, quantitation kits, and cell based assay systems, as well as technology transfer service. PanGen Biotech Inc. was founded in 1999 and is based in Suwon-si, South Korea.
Corporate Governance
PanGen Biotech Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available